Jimenez-Luna Cristina, González-Flores Encarnación, Ortiz Raul, Martínez-González Luis J, Antúnez-Rodríguez Alba, Expósito-Ruiz Manuela, Melguizo Consolación, Caba Octavio, Prados Jose
Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain.
Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, 18071 Granada, Spain.
J Clin Med. 2021 May 22;10(11):2248. doi: 10.3390/jcm10112248.
Genes involved in the angiogenic process have been proposed for the diagnosis and therapeutic response of metastatic colorectal cancer (CRC). This study aimed to investigate the value of , , and -circulating RNA as biomarkers in metastatic CRC. Blood cells and serum mRNA from 59 patients with metastatic CRC and 47 healthy controls were analyzed by digital PCR. The area under the receiver operating characteristic curve (AUC) was used to estimate the diagnostic value of each mRNA alone or mRNA combinations. A significant upregulation of the , and genes in blood cells and serum samples from metastatic CRC patients was detected. Circulating mRNA levels in the serum of all genes were significantly more abundant than in blood. The highest discrimination ability between metastatic CRC patients and healthy donors was obtained with (AUC of 0.984) and (AUC of 0.896) in serum samples. Biomarker combinations did not improve the discriminatory capacity of biomarkers separately. Analyzed biomarkers showed no correlation with overall survival or progression-free survival, but and / expression in serum correlated significantly with the response to antiangiogenic agents. These findings demonstrate that assessment of genes involved in the angiogenic process may be a potential non-invasive diagnostic tool for metastatic CRC and its response to antiangiogenic therapy.
参与血管生成过程的基因已被提出用于转移性结直肠癌(CRC)的诊断和治疗反应评估。本研究旨在探讨[具体基因名称未给出]、[具体基因名称未给出]、[具体基因名称未给出]和[具体基因名称未给出]循环RNA作为转移性CRC生物标志物的价值。采用数字PCR分析了59例转移性CRC患者和47例健康对照者的血细胞和血清mRNA。用受试者工作特征曲线下面积(AUC)评估每个mRNA单独或mRNA组合的诊断价值。检测到转移性CRC患者血细胞和血清样本中[具体基因名称未给出]、[具体基因名称未给出]和[具体基因名称未给出]基因显著上调。所有基因血清中的循环mRNA水平均显著高于血细胞。在血清样本中,[具体基因名称未给出](AUC为0.984)和[具体基因名称未给出](AUC为0.896)对转移性CRC患者和健康供体的区分能力最强。生物标志物组合并未单独提高生物标志物的区分能力。分析的生物标志物与总生存期或无进展生存期无相关性,但血清中[具体基因名称未给出]和[具体基因名称未给出]/[具体基因名称未给出]表达与抗血管生成药物的反应显著相关。这些发现表明,评估参与血管生成过程的基因可能是转移性CRC及其对抗血管生成治疗反应的一种潜在非侵入性诊断工具。